Northern Trust Corp Coherus Bio Sciences, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 896,735 shares of CHRS stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

896,735

Previous 913,746 1.86%

Holding current value

$1.25 Million

Previous $1.58 Million 41.01%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.99 - $1.8 $16,840 - $30,619	-17,011 Reduced 1.86%	896,735 $932,000
Q2 2024 Aug 14, 2024	SELL	$1.58 - $2.51 $12,474 - $19,816	-7,895 Reduced 0.86%	913,746 $1.58 Million
Q1 2024 May 14, 2024	SELL	$2.02 - $3.14 $89,641 - $139,343	-44,377 Reduced 4.59%	921,641 $2.2 Million
Q4 2023 Feb 13, 2024	BUY	$1.59 - $3.85 $5,840 - $14,141	3,673 Added 0.38%	966,018 $3.22 Million
Q3 2023 Nov 13, 2023	BUY	$3.74 - $5.45 $621,243 - $905,288	166,108 Added 20.86%	962,345 $3.6 Million
Q2 2023 Aug 11, 2023	BUY	$3.79 - $8.3 $123,436 - $270,322	32,569 Added 4.26%	796,237 $3.4 Million
Q1 2023 May 15, 2023	BUY	$5.89 - $10.52 $74,496 - $133,056	12,648 Added 1.68%	763,668 $5.22 Million
Q4 2022 Feb 13, 2023	SELL	$5.69 - $10.07 $34,731 - $61,467	-6,104 Reduced 0.81%	751,020 $5.95 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $73,707 - $142,583	10,280 Added 1.38%	757,124 $7.28 Million
Q2 2022 Aug 12, 2022	BUY	$5.86 - $13.23 $244,033 - $550,950	41,644 Added 5.91%	746,844 $5.41 Million
Q1 2022 May 13, 2022	SELL	$10.92 - $16.41 $282,849 - $425,051	-25,902 Reduced 3.54%	705,200 $9.1 Million
Q4 2021 Feb 08, 2022	SELL	$15.81 - $18.99 $160,186 - $192,406	-10,132 Reduced 1.37%	731,102 $11.7 Million
Q3 2021 Nov 15, 2021	SELL	$12.68 - $17.79 $243,139 - $341,123	-19,175 Reduced 2.52%	741,234 $11.9 Million
Q2 2021 Aug 13, 2021	BUY	$12.95 - $15.41 $513,260 - $610,759	39,634 Added 5.5%	760,409 $10.5 Million
Q1 2021 May 12, 2021	SELL	$14.42 - $21.39 $505,392 - $749,676	-35,048 Reduced 4.64%	720,775 $10.5 Million
Q4 2020 Feb 11, 2021	SELL	$16.56 - $18.94 $296,804 - $339,461	-17,923 Reduced 2.32%	755,823 $13.1 Million
Q3 2020 Nov 16, 2020	SELL	$17.41 - $19.89 $619,082 - $707,268	-35,559 Reduced 4.39%	773,746 $14.2 Million
Q2 2020 Aug 14, 2020	BUY	$14.43 - $19.16 $414,299 - $550,102	28,711 Added 3.68%	809,305 $14.5 Million
Q1 2020 May 14, 2020	BUY	$11.67 - $22.53 $22,908 - $44,226	1,963 Added 0.25%	780,594 $12.7 Million
Q4 2019 Feb 14, 2020	SELL	$16.33 - $21.37 $205,676 - $269,155	-12,595 Reduced 1.59%	778,631 $14 Million
Q3 2019 Nov 13, 2019	BUY	$16.3 - $23.37 $1.54 Million - $2.21 Million	94,773 Added 13.61%	791,226 $16 Million
Q2 2019 Aug 13, 2019	BUY	$13.1 - $22.1 $417,025 - $703,531	31,834 Added 4.79%	696,453 $15.4 Million
Q1 2019 May 13, 2019	BUY	$8.38 - $15.5 $117,948 - $218,162	14,075 Added 2.16%	664,619 $9.07 Million
Q4 2018 Feb 12, 2019	SELL	$8.65 - $16.28 $91,897 - $172,958	-10,624 Reduced 1.61%	650,544 $5.89 Million
Q3 2018 Nov 14, 2018	BUY	$14.45 - $20.25 $1.37 Million - $1.91 Million	94,468 Added 16.67%	661,168 $10.9 Million
Q2 2018 Sep 18, 2018	SELL	$10.25 - $17.45 $18,419 - $31,357	-1,797 Reduced 0.32%	566,700 $7.93 Million
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $934,769 - $1.59 Million	91,197 Added 19.11%	568,497 $7.96 Million
Q1 2018 May 09, 2018	BUY	$9.1 - $13.7 $79,716 - $120,012	8,760 Added 1.87%	477,300 $5.27 Million
Q4 2017 Feb 14, 2018	SELL	$8.35 - $14.4 $1,068 - $1,843	-128 Reduced 0.03%	468,540 $4.12 Million
Q3 2017 Nov 13, 2017	BUY	$11.1 - $14.5 $5.2 Million - $6.8 Million	468,668	468,668 $6.26 Million

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

78M

Call Options Held

40.7K

Put Options Held

50.1K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $108M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Coherus Bio Sciences, Inc. Transaction History